Etanercept Tedavisinin Deneysel Endometriozisli Sıçan Modelinde Serum Malonaldialdehid Düzeylerine Etkisi

Abstract

Amaç: Amacımız oluşturulan deneysel endometriozisli sıçan modelinde etanerceptin endometriozisi tedavi edebilme yeteneğini serum lipid peroksidasyonuna olan etkisi üzerinden değerlendirmekti.

Yöntem: Bu deneysel çalışmada 30 adet Wistar albino cinsi dişi sıçan kullanıldı. Sıçanlardan 20’sinde endometriozis modeli cerrahi olarak oluşturulurken, 10’unda ise anestezi ve cerrahinin etkisini dışlamak amacıyla yalancı operasyon uygulandı. İlk operasyondan 4 hafta sonra sıçanların ektopik endometrial doku volümleri ikinci bir operasyonla değerlendirildi ve kan alındı. Daha sonra sıçanlar 3 gruba ayrıldı: Grup I (herhangi bir tedavi almamış, yalancı operasyon, n=10), grup II (2 ml/gün subkutan serum fizyolojik, endometriozis modeli, n=10), grup III (2 mg/kg/haftada 3 kez, subkutan etanercept, endometriozis modeli, n=10). İki haftalık tedavi sonrası sıçanların 3. operasyonla ektopik endometrial doku volümleri değerlendirildi ve 2. kanları alındı. Serum malondialdehid (MDA) düzeyleri spektrofotometrik olarak analiz edildi.

Bulgular: Tedavi sonrası dönemde ektopik endometrial doku volümleri karşılaştırıldığında grup III te grup II ye göre anlamlı düşük sonuçlar elde edildi (p=0.000). Aynı zamanda grup III tedavi sonrası dönemde, tedavi öncesi döneme göre anlamlı düşük doku volüm değerleri gösterdi (p=0.005). Tedavi sonrası dönemde ise MDA düzeylerinde gruplar arası anlamlı farklılık mevcuttu (p=0.001). Tedavi sonrası dönemde MDA düzeyleri Grup III te grup II ye göre anlamlı düşüktü (p=0.001). Ek olarak, grup III te MDA düzeyleri tedavi sonrası dönemde öncesine göre anlamlı düşüktü (p=0.028).

Sonuç: Çalışmamızın sonuçları bize etanerceptin serum lipid peroksidasyonu düşürücü etkisini ve endometriozis tedavisinde etkili bir şekilde kullanılabileceğini düşündürmektedir.

Keywords

• Endometriozis,etanercept,malondialdehid,lipit peroksidasyonu,oksidatif stres

The Effect Of Etanercept Treatment On Serum Malonaldialdehyde Levels In Experimental Endometriosis Rats Model

Abstract

Objectives: The purpose of this study was to evaluate the serum lipid peroxidation in rats with experimental endometriosis who received etanercept (anti-tumor necrosis factor alpha) treatment.

Methods: In this experimental study, 30 Wistar albino female rats were used. The surgical endometriosis model operation applied to 20 rats from those, in the 10's sham operation was performed in order to exclude the effects of anesthesia and surgery. Ectopic endometrial implants volumes of rats 4 weeks after the first operation were evaluated and blood samples were taken with a second operation. Then the rats were divided into 3 groups: Group I (did not receive any treatment, false operation, n = 10), group II (2 ml / day subcutaneous saline, endometriosis model, n = 10), group III (2 mg / kg / week etanercept subcutaneously 3 times, endometriosis model, n = 10). 3. After two weeks of treatment, ectopic endometrial implants volumes were evaluated with and second blood samples were taken from rats. Serum malondialdehyde (MDA) levels were analyzed by spectrophotometry.

Results: The ectopic endometrial implant volumes of group III showed significantly lower results than group II in the post-treatment period (p =0.000). According to the same time group III implants showed significantly lower volume in the post-treatment period before the treatment (p = 0.005). In the post-treatment period, there was a significant difference between the groups in the MDA levels (p = 0.001), and group III was showed significantly lower levels of MDA compared to group II (p = 0.001). In addition, pre-treatment levels of MDA were also significantly lower compared to post-treatment period in group III (p = 0.028).

Conclusion: In summary, these results suggest that etanercept has protective effects against endometriosis in rats, which may be attributed to attenuating oxidative stress

Keywords

• Endometriosis,etanercept,malondialdehyde,lipid peroxidation,oxidative stress

References

1. Selçuk I, Bozdağ G. Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of the literature. J Turk Ger Gynecol Assoc. 2013; 14 (2): 98-103.
2. Fadhlaoui A, Bouquet de la Jolinière J, Feki A. Endometriosis and infertility: how and when to treat? Front Surg. 2014; 1: 24.
3. Lambrinoudaki IV, Augoulea A, Christodoulakos GE ve diğ. Measurable serum markers of oxidative stress response in women with endometriosis. Fertil Steril. 2009; 91(1):46-50.
4. Shanti A, Santanam N, Morales AJ ve diğ. Autoantibodies to markers of oxidative stress are elevated in women with endometriosis. Fertil Steril. 1999; 71 (6):1115-1118.
5. Prieto L, Quesada JF, Cambero O ve diğ. Analysis of follicular fluid and serum markers of oxidative stress in women with infertility related to endometriosis. Fertil Steril. 2012; 98(1):126-130.
6. Barroso RP, Osuamkpe C, Nagamani M ve diğ. Nitric oxide inhibits development of embryos and implantation in mice. Mol Hum Reprod. 1998; 4: 503-507.
7. Ho YS, Gargano M, Cao J ve diğ. Reduced fertility in female mice lacking copper-zinc superoxide dismutase. J Biol Chem. 1998; 273 (13): 7765-7769.
8. Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin North Am. 2015; 42(1): 87-101.

9. Zito G, Luppi S, Giolo E ve diğ. Medical treatments for endometriosis-associated pelvic pain. Biomed Res Int. 2014; 2014:191967.
10. Islimye M, Kilic S, Zulfikaroglu E ve diğ. Regression of endometrial autografts in a rat model of endometriosis treated with etanercept. Eur J Obstet Gynecol Reprod Biol. 2011; 159(1):184-189.
11. Yildirim G, Attar R, Ficicioglu C ve diğ. Etanercept causes regression of endometriotic implants in a rat model. Arch Gynecol Obstet. 2011; 283(6):1297-302.
12. Van Vollenhoven RF, Østergaard M, Leirisalo-Repo M ve diğ. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2015; pii: annrheumdis-2014-205726.
13. Woolacott N, Hawkins N, Mason A ve diğ. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006; 10(46):1-233.
14. Dretzke J, Edlin R, Round J ve diğ. A systematic review and economic evaluation of the use of tumour necrosis factoralpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011; 15(6):1-244.
15. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985; 44:684-694.
16. D'souza D, Subhas BG, Shetty SR ve diğ. Estimation of serum malondialdehyde in potentially malignant disorders and post-antioxidant treated patients: A biochemical study. Contemp Clin Dent. 2012; 3(4): 448-451.
17. Oner-Iyidoğan Y, Koçak H, Gürdöl F ve diğ. Indices of oxidative stress in eutopic and ectopic endometria of women with endometriosis. Gynecol Obstet Invest. 2004; 57(4):214-217.
18. Agarwal A, Gupta S, Sharma R. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005; 3:1– 21.
19. Murphy AA, Santanam N, Morales AJ ve diğ. Lysophospha- tidyl-choline, a chemotactic factor for monocytes/ T lymphocytesis elevated in endometriosis. J Clin Endocrinol Metab. 1998; 83:2110–2113.
20. Valko M, Rhodes CJ, Moncol J ve diğ. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006; 160:1-40.
21. Rosa e Silva JC, do Amara VF, Mendonça JL ve diğ. Serum markers of oxidative stress and endometriosis. Clin Exp Obstet Gynecol. 2014; 41(4):371-374.
22. Yang M, Chen J, Zhao J ve diğ. Etanercept attenuates myocardial ischemia/reperfusion injury by decreasing inflammation and oxidative stress. PLoS One. 2014; 9(9):108024.
23. Bacchetti T, Campanati A, Ferretti G ve diğ. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol. 2013; 168(5):984-989.